KYTHERA Biopharmaceuticals (FRA:KYT) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is KYTHERA Biopharmaceuticals 5-Year Dividend Growth Rate?

KYTHERA Biopharmaceuticals's Dividends per Share for the three months ended in Jun. 2015 was €0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

KYTHERA Biopharmaceuticals's Dividend Payout Ratio for the three months ended in Jun. 2015 was 0.00. As of today, KYTHERA Biopharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of KYTHERA Biopharmaceuticals's 5-Year Dividend Growth Rate

For the Drug Manufacturers - General subindustry, KYTHERA Biopharmaceuticals's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KYTHERA Biopharmaceuticals's 5-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KYTHERA Biopharmaceuticals's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where KYTHERA Biopharmaceuticals's 5-Year Dividend Growth Rate falls into.

KYTHERA Biopharmaceuticals 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

KYTHERA Biopharmaceuticals (FRA:KYT) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

KYTHERA Biopharmaceuticals's Dividend Payout Ratio for the quarter that ended in Jun. 2015 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2015 )	/	EPS without NRI (Q: Jun. 2015 )
	=	0	/	-1.283
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KYTHERA Biopharmaceuticals 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

KYTHERA Biopharmaceuticals (FRA:KYT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KYTHERA Biopharmaceuticals Inc (FRA:KYT) » Definitions » 5-Year Dividend Growth Rate

Traded in Other Exchanges

N/A

Address

Website

http://www.kytherabiopharma.com

KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

KYTHERA Biopharmaceuticals (FRA:KYT) Headlines

No Headlines